Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jan 08, 2021 12:20pm
186 Views
Post# 32254475

RE:Regaining credibility

RE:Regaining credibilityYou are exactly right about that and it is important given how the company had lost so much credibility with its too high sales forecasts on both their commercial products. But I think they gained the most credibility, and also avoided losing another sizable chunk of credibility, by getting the phase III go ahead from the FDA. That was a high risk/high reward call that could have blown up in their faces. Analysts did not believe them and we had our doubts on this board as well. But they were right and that helps a lot. 

If we get guidance, I suspect it would only be for the quarter and maybe for the full year, but not for two quarters. I have not seen companies give two quarters of guidance. I hope they do give guidance and make it low enough that they beat it easily. 

palinc2000 wrote: Yesterday s PR is really a credibility builder IMO
When Paul t said hat the Filing with FDA was imminent,,,It proved to be exactly that
When Pau said  that he was making adjustments in September to get better sales results in the context of the pandemic ......It proved to be exactly that 

Ny next catalyst will be the 4 th Quarter Results CC during which I am hoping that he will give guidance for the 1st Quarter  sales and  hopefully  for the second quarter also





<< Previous
Bullboard Posts
Next >>